LearnGlossaryMarketStocksSuperinvestorsSign in

ATAI

Atai Beckley Inc.

Healthcare · $2.7B market cap

Verdict

We can't put a fair value on ATAI right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-18.2% a year✗
Sales growth-33.1% a year✗
Free cash flow growth—?
Return on invested capital-50.4%✗

Follow ATAI

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ATAI. In Q1 2026, 1 opened a position. Who we track

Ruane Cunniff LP

Ruane Cunniff LP · as of Q2 2026

$222K

42,112 shares

Moves in Q1 2026

New position: Ruane Cunniff LP

About Atai Beckley Inc.

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Sep 11, 2026. How the Payback Price works